Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

CP-506 is a hypoxia-activated DNA alkylating agent specifically designed to have a bystander effect, aqueous solubility, oral bioavailability, and no off-mechanism activation by the human aerobic reductase AKR1C3

Antineoplastic agent, ATC Code: LO1X A02

Drug that blocks immune checkpoint proteins: PD-1, PD-L1, CTLA-4